Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridgeshire based Founder operating in the Medical Device space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Oliver Armitage
Co-Founder & CSO of BIOS
Oliver Armitage is Co-Founder and Chief Scientific Officer at BIOS, a leading neural engineering startup. Oliver has always had a vision that the human body could be repaired or made better through augmentative technology and how that can be used to improve people’s lives. He studied for his PhD at the University of Cambridge in Bioengineering, working in the world-renowned Nanoscience Centre. He specializes in tissue interfaces and engineering to allow technology to be fused with the body. Oliver was recently named to Forbes 30 Under 30 2018.
Follow Oliver Armitage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Mosin Badkar
Co-Founder and VP of Cardiac Design Labs
Mosin Badkar is responsible for product R and D and Algorithms. His scope includes design of new products, prototyping of design and proof of concept. His scope also includes planning and tracking of new product designs, system level and various software development activities.
Follow Mosin Badkar:
About Cardiac Design Labs: Cardiac Design Labs is into designing, developing, deploying and selling intelligent devices for medical purpose.
Eoin McKinney
Chief Scientific Officer & Co-Founder of PredictImmune
Eoin is a Wellcome-Beit intermediate Research Fellow in the Department of Medicine at the University of Cambridge and an honorary consultant in nephrology and transplantation in Cambridge University NHS hospitals Foundation Trust. He obtained a first-class degree in pre-clinical medicine from Keble College, Oxford University in 1999 and graduated in clinical medicine with honours from Edinburgh University in 2002. His primary interest is the use of systems immunology approaches to translate high throughput analyses of autoimmune disease datasets into clinical practice.
Follow Eoin McKinney:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Kenneth Smith
Co-Founder & Chief Medical Officer of PredictImmune
Professor Ken Smith is Professor of Medicine and Head of the Department of Medicine at the University of Cambridge. He trained in nephrology (FRACP, FRCP) and clinical immunology (FRCPA) and completed a PhD at the WEHI in Melbourne. His laboratory runs a translational programme in autoimmune disease (particularly inflammatory bowel disease, vasculitis and SLE) that has led to the discovery of a novel prognosis-predicting biomarker currently in clinical trials and the identification of genes and pathways involved in disease pathogenesis.
Follow Kenneth Smith:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Oriane Chausiaux
Founder Director – CSO, Serial Entrepreneur of Heartfelt Technologies
Follow Oriane Chausiaux:
About Heartfelt Technologies: Heartfelt Technologies are developing the only home-based heart failure monitor that does not require patient interaction or compliance.
Anurag Agarwal
Founder of The Cambridge Stethoscope Company
Follow Anurag Agarwal:
About The Cambridge Stethoscope Company: The Cambridge Stethoscope Company is developing the world’s first intelligent stethoscope that is capable of automated diagnosis.
Billy Boyle
CEO and Co-Founder of Owlstone Nanotech
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners. He is also active in business development, demonstrating to partners how the Owlstone technology can used to realise a paradigm shift in detection applications and deployment scenarios. Billy is heavily involved in the creation and realisation of new technologies and IP. Prior to joining Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Follow Billy Boyle:
About Owlstone Nanotech: OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
